Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News December 16th 2011

December 16th 2011

National diabetes Audit (NDA) Mortality Analysis 2007-2008
The primary purpose of this mortality analysis is to provide an initial assessment of the feasibility of using the mortality linked NDA data to provide meaningful measures of mortality in people with diabetes (NHS)

Atlas of Variation 2011
Download of Map 6: Percentage of people in the National Diabetes Audit (NDA) with Type 1 diabetes receiving all nine key care processes by PCT here (NHS)

Assessment of the under-reporting of diabetes in hospital admission data: a study from the Scottish Diabetes Research Network Epidemiology Group
Linkage of diabetes register data to hospital admissions data provides a more accurate source for measuring hospital admissions among people diagnosed with diabetes than hospital admissions data (Diabetic Medicine)

The current status of diabetes professional educational standards and competencies in the UK
Position Statement from the Diabetes UK Healthcare Professional Education Competency Framework Task and Finish Group (Diabetic Medicine)

Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 Diabetes
Subjects with type 2 diabetes not on prandial insulin who used RT-CGM intermittently for 12 weeks significantly improved glycemic control at 12 weeks and sustained the improvement without RT-CGM during the 40-week follow-up period, compared with those who used only SMBG (Diabetes Care)

Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients
Evidence from a 37,229 patient meta-analysis (American Heart Journal)

Effects of lifestyle intervention in persons at risk for type 2 diabetes
It is possible to achieve important lifestyle changes in persons at risk for type 2 diabetes with modest clinical efforts. Group intervention yields no additional effects (BMC Public Health)

PPAR? as a therapeutic target in diabetic nephropathy and other renal diseases
Peroxisome proliferator-activated receptor gamma (PPAR) agonists are effective in delaying and even preventing the progression of many renal diseases, especially diabetic nephropathy. PPAR? may represent a promising target for the treatment of renal diseases (Current Opinion in Nephrology & Hypertension)

Assessment of Automated Disease Detection in Diabetic Retinopathy Screening Using Two-Field Photography
Automated grading can safely reduce the workload of manual grading using two field, mydriatic photography in a routine screening service (PLoS ONE)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNovo NordiskNapp Diabetes

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership